Soliqua for Gastroparesis

lixisenatide · Investigational / off-label

Last updated 2026-05-28 15:46 UTC

Soliqua (lixisenatide) is not FDA-approved for gastroparesis, and any use for this condition is off-label or investigational. The listed research examines lixisenatide's effects on gastric emptying in preclinical and type 2 diabetes studies but does not address its use in gastroparesis.

AI summary of the sources below.

Drug	Soliqua (lixisenatide)
Condition	Gastroparesis
Approval status	Investigational / off-label
Research papers	2

Soliqua is not FDA-approved for gastroparesis; the research below reflects investigational or off-label study only.

Research on lixisenatide for gastroparesis (2)

Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence. J Diabetes Complications · 2014 · 41 citations
Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures. J Diabetes Complications · 2024 · 8 citations

Search PubMed ↗